膀胱尿路上皮癌组织中HMGA2蛋白表达及其临床意义

目的 探讨高迁移率族蛋白A2(high mobility group protein A2,HMGA2)在膀胱癌组织中的表达情况,并分析其与临床病理特征及复发的关系.方法 膀胱尿路上皮癌标本148例,正常膀胱组织标本30例,采用免疫组织化学方法检测2组标本组织中HMGA2蛋白的表达,并结合临床资料进行分析.结果 正常膀胱组织中无HMGA2蛋白表达,肿瘤组织中随病理分级和分期增加,HMGA2蛋白相对表达量逐渐增高.HMGA2蛋白在G1、G2、G3组织中表达阳性率分别为21.3%、60.3%、82.1%,差异有统计学意义(P＜0.001).非肌层浸润性膀胱尿路上皮癌和肌层浸润性膀胱尿路上皮癌中HMGA2蛋白表达的阳性率分别为43.3%和72.7%,差异有统计学意义(P=0.003).随访2～95个月,复发64例,复发组与未复发组中HMGA2蛋白表达阳性率分别为54.7%和25.0%,差异有统计学意义(P=0.007).结论 HMGA2蛋白表达在膀胱癌组织中明显高于正常组织,HMGA2蛋白表达与膀胱癌的分级、分期、复发有关;与患者年龄、性别、肿瘤数目无相关性.检测HMGA2蛋白有助于膀胱癌的诊断及预后的评估.

Abstract：

Objective This study was to explore the expression and significance of HMA2 in bladder cancer , analyze its correlations to clinicopathologic and recurrence of bladder cancer. Methods The expression of HMGA2 protein in 148 specimens of bladder cancer and 30 specimens of normal bladder tissues was detected by immunohistochemtry, its correlations to clinicopathologic features was analyzed. Results There was no expression of HMGA2 protein in normal bladder tissues,while the expression level of HMGA2 protein was getting higher with the increase of tumor pathology grade and stage. The positive rate of HMGA2 protein was 21.3% in G1 bladder cancer, 60. 3% in G2 bladder cancer, 82.1% in G3 bladder cancer, its difference is significant (P＜0. 001). It was significantly lower in non-muscle invasive bladder cancer than in muscle invasive bladder cancer (43.3% vs 72. 7%, P=0. 003). The patients were followed up for 2～95 months, patients of recurrence was 64,HMGA2 protein expression was significantly higher in patients with recurrence than with non-recurrence (54.7% vs 25.0%, P=0. 007). Conclusions The expression of HMGA2 protein was highly in bladder cancer, the positive rate of HMGA2 protein expression was related with classification,TMN stage and recurrence, but not with sex, age, tumor number (P＞0. 05). The detection of the expression of HMGA2 protein is in favor of diagnosis and prognostic evaluation of bladder cancer.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

雌激素受体-β在膀胱尿路上皮癌中的表达及其临床意义

目的 观察雌激素受体β(ER-β)在膀胱癌中的表达及其与临床病理特征的关系,探讨其临床意义.方法 采用免疫组织化学SP法检测ER-β蛋白在146例膀胱尿路上皮癌和25例正常膀胱黏膜中的表达.结果 ER-β蛋白在膀胱癌组织中阳性表达率为44.5%,在正常膀胱黏膜组织阳性表达率为20.0%,差异有统计学意义(P＜0.05).ER-β的表达率随着膀胱癌病理分级和临床分期的升高而增高(P＜0.05),而且与患者性别明显相关,女性阳性率显著高于男性患者(P＜0.05).结论 ER-β在膀胱癌组织中表达有明显的性别差异,且与膀胱癌的分化和浸润性进展密切相关,提示ER-β蛋白可能在膀胱癌的发生发展中起重要作用.

Abstract：

Objective To investigate the expression of estrogen receptor beta (ER-β) in bladder urothelial carcinoma and to explore its clinical significance.Methods Immunohistochemical SP method was employed to detected the expression of ER-β in bladder cancer tissue ( 146 cases) and the normal controls (25 cases).In addition,clinicopathological data of them were analyzed.Results The positive expression rate of ER-β in bladder cancer tissue was 44.5%,but low positive expression rate (20.0% )was found in normal bladder tissue.The expression of ER-β was markedly associated with tumor pathological grade and clinical stage ( P＜0.05).Moreover,the expression of ER-β was observed more frequently in female (59.6%) than male (37.4%) (P＜0.05 ).Conclusion The sex difference in expression of ER-β is associated with differentiation and invasion in bladder urothelial carcinoma,it implies that ER-β might play important roles in the development and progression of bladder cancer.     

非肌层浸润性膀胱癌患者术前是否需要常规行IVU检查

Objective To discuss the need for performing intravenous urography(IVU) in patients with non-muscle invasive bladder cancer before surgery. Methods From 1997 to 2008,1968patients were diagnosed as non-muscle invasive carcinoma of the bladder with pathological confirmation. All patients underwent ultrasonography, cystoscopy and IVU prior to surgrey. The x2 test was used for statistical analysis. Results The incidence of upper urinary tract urothelial tumors (UUTUT) was 11. 0% (216 cases). Two hundred and fifteen (13. 6%) suffered simultaneous UUTUT detected by IVU in 1528 patients with bladder cancer who had intermittent painless gross hematuria, while only 1 (0.3 %) suffered simultaneous UUTUT in 386 non-symptomatic patients (P＜0.01). Among 120 patients with bladder cancer whose upper tract was abnormal detected by ultrasonography,120 (100. 0%) suffered simultaneous UUTUT detected by IVU, and of 1848 patients who were normal in upper tract by ultrasonography, 96 (5. 2%) suffered simultaneous UUTUT detected by IVU (P＜0. 01). Of the patients with no abnormalities in upper tract by ultrasound, 37(3. 0%) suffered simultaneous UUTUT detcted by 1VU in 1247 patients with single bladder tumor,and 59 (9.8%) suffered simultaneous UUTUT in 601 patients with multiple bladder tumors (P＜0.01). Of the patients with single bladder tumor who had no abnormalities in upper tract by ultrasonography, 2 (0.2%) suffered simultaneous UUTUT detected by IVU in 822 patients with the diameter of the tumor＜1.0 cm, and 35 (8. 2 %) suffered simultaneous UUTUT in 425 patients with the diameter≥1. 0 cm (P＜0.01). Of the 1541 patients with histological G1, 48 (3.1%) suffered simultaneous UUTUT detected by IVU, and of the 427 patients with histological G2- G3, 168 (39. 3%)suffered simultaneous UUTUT (P ＜ 0. 01 ). Conclusion Patients with the following characters should undergo IVU before surgery: hematuria, abnormal upper urinary tract by ultrasonography,multifocal tumours, the diameter of the single bladder tumor≥1. 0 cm and high gradc tumors.     

非肌层浸润性膀胱癌患者术前是否需要常规行IVU检查

Objective To discuss the need for performing intravenous urography(IVU) in patients with non-muscle invasive bladder cancer before surgery. Methods From 1997 to 2008,1968patients were diagnosed as non-muscle invasive carcinoma of the bladder with pathological confirmation. All patients underwent ultrasonography, cystoscopy and IVU prior to surgrey. The x2 test was used for statistical analysis. Results The incidence of upper urinary tract urothelial tumors (UUTUT) was 11. 0% (216 cases). Two hundred and fifteen (13. 6%) suffered simultaneous UUTUT detected by IVU in 1528 patients with bladder cancer who had intermittent painless gross hematuria, while only 1 (0.3 %) suffered simultaneous UUTUT in 386 non-symptomatic patients (P＜0.01). Among 120 patients with bladder cancer whose upper tract was abnormal detected by ultrasonography,120 (100. 0%) suffered simultaneous UUTUT detected by IVU, and of 1848 patients who were normal in upper tract by ultrasonography, 96 (5. 2%) suffered simultaneous UUTUT detected by IVU (P＜0. 01). Of the patients with no abnormalities in upper tract by ultrasound, 37(3. 0%) suffered simultaneous UUTUT detcted by 1VU in 1247 patients with single bladder tumor,and 59 (9.8%) suffered simultaneous UUTUT in 601 patients with multiple bladder tumors (P＜0.01). Of the patients with single bladder tumor who had no abnormalities in upper tract by ultrasonography, 2 (0.2%) suffered simultaneous UUTUT detected by IVU in 822 patients with the diameter of the tumor＜1.0 cm, and 35 (8. 2 %) suffered simultaneous UUTUT in 425 patients with the diameter≥1. 0 cm (P＜0.01). Of the 1541 patients with histological G1, 48 (3.1%) suffered simultaneous UUTUT detected by IVU, and of the 427 patients with histological G2- G3, 168 (39. 3%)suffered simultaneous UUTUT (P ＜ 0. 01 ). Conclusion Patients with the following characters should undergo IVU before surgery: hematuria, abnormal upper urinary tract by ultrasonography,multifocal tumours, the diameter of the single bladder tumor≥1. 0 cm and high gradc tumors.     

化疗对CD133+结肠癌细胞的作用效果

目的 观察化疗前后结肠癌细胞株HT29、SW620中CD133+结肠癌细胞的数量变化,探讨化疗对CD133+结肠癌细胞的作用效果.方法 取对数生长的结肠癌细胞株HT29、SW620,采用80 mg/L 5-氟尿嘧啶(5-Fu)和25 mg/L奥沙利铂(Oxaliplatin)分别作用8 h,并设对照组,利用CD133抗体进行标记后再用流式细胞仪进行检测,观察化疗前后CD133+细胞的比例.结果 流式细胞仪检测结肠癌细胞株HT29,80 mg/L 5-Fu处理8 h组中CD133+肿瘤细胞为45.00%,与未处理组(32.80%)比较结果差异有统计学意义(P＜0.01);25 mg/L奥沙利铂处理8 h组中CD133+肿瘤细胞为55.30%,与未处理组和80 mg/L 5-Fu处理8 h组比较结果差异有统计学意义(P＜0.01).流式细胞仪检测结肠癌细胞株SW620,80 mg/L 5-Fu处理8 h组中CD133+肿瘤细胞为47.10%,与未处理组(33.90%)比较结果差异有统计学意义(P＜0.01);25 mg/L奥沙利铂处理8 h组中CD133+肿瘤细胞为56.50%,与未处理组和80 mg/L 5-Fu处理8 h组比较结果差异有统计学意义(P＜0.01).结论 CD133+结肠癌细胞能明显抵抗化疗.

Abstract：

Objective To observe the changes of quantity of CD133 + cells in HT29 and SW620 cell lines before and after chemotherapy, and detect the effect of chemotherapy on CD133 + cells. Methods HT29 and SW620 cells in logarithmic growth phase were separately treated with 80 mg/L 5-fluorouracil(5-Fu) and 25 mg/L oxaliplatin for 8 h, and analyzed by flow cytometry after being marked by CD133 antibody. The proportion of CD133 + cells before and after chemotherapy was measured. Results For HT29 cells, the proportion of CD133 + cancer cells in the group treated with 80 mg/L 5-Fu for 8 h was 45.00% with the difference being remarkable ( P ＜ 0. 01 ) compared to the non-treatment group ( 32. 80% ). The proportion of CD133 + cancer cells in the group treated with 25 mg/L oxaliplatin for 8 h was 55.30% with the difference being remarkable ( P ＜ 0. 01 ) compared with both the non-treatment group and the group treated with 80 mg/L 5-Fu for 8 h. For SW620 cells, the proportion of CD133 + cancer cells in the group treated with 80 mg/L 5-Fu for 8 h was 47. 10% with the difference being remarkable ( P ＜0. 01 ) compared with the non-treatment group (33.90%). The proportion of CD133 + cancer cells in the group treated with 25 mg/L oxaliplatin for 8 h was 56. 50% with the difference being remarkable ( P ＜ 0. 01 ) compared with both the non-treatment group and the group treated with 80 mg/L 5-Fu for 8 h. Conclusion CD133 positive colon cancer cells have anti-chemotherapy activity obviously.     

趋化因子受体7在膀胱癌组织中的表达及其临床意义

目的 探讨趋化因子受体7(CXCR7)蛋白在膀胱癌中的表达情况,并分析其与临床生物学行为及复发的关系.方法 选择148例膀胱移行细胞癌标本,30例正常膀胱组织标本:肿瘤标本中非肌层浸润性癌104例,肌层浸润性癌44例;G147例、G2 73例、G3 28例;单发肿瘤89例,多发肿瘤59例;非肌层浸润性癌中未复发40例,复发64例.采用LSAB免疫组织化学方法,检测膀胱癌和正常组织中CXCR7蛋白的表达,并结合临床资料进行分析. 结果正常组织中CXCR7蛋白的表达水平为10.0%(3/30),肿瘤组织为85.1%(126/148);单发及多发肿瘤CXCR7蛋白高表达率分别为49.4%(44/89)和71.2%(42/59),G1、G2、G3膀胱癌CXCR7蛋白高表达阳性率分别为34.0%(16/47)、65.8%(48/73)、78.6%(22/28),差异均有统计学意义(P＜0.01).非肌层浸润性肿瘤和肌层浸润性肿瘤中CXCR7蛋白高表达阳性率为51.9%和72.7%,组间差异有统计学意义(P＜0.05).非肌层浸润性膀胱癌中,复发组与未复发组中CXCR7蛋白高表达阳性率为64.1%和32.5%,差异有统计学意义(P＜0.01).Kaplan-Merier曲线显示,CXCR7蛋白高表达组患者和CXCR7蛋白低表达组患者术后无复发生存率比较,差异有统计学意义(P＜0.01). 结论CXCR7蛋白高表达与膀胱移行细胞癌的恶性程度及预后相关,提示CXCR7与膀胱癌的发生发展存在相关性.

Abstract：

Objective To explore the expression of CXCR7 in bladder cancer and analyze its clinical significance and relationship with bladder cancer recurrence. Methods The expressions of CXCR7 protein in 148 specimens of bladder cancer and 30 specimens of normal bladder tissues were detected by immunohistochemical staining and its clinical significance was then analyzed. Results The expression of CXCR7 protein was higher in bladder cancers than in the adjacent normal tissues (P＜0.01). CXCR7 protein expression rates were 49. 4% and 71.2% in mutifocal tumors and unifocal tumors, while 34.0%, 65.8% and 78. 6% in G1, G2, and G3 tumors, respectively (P＜0. 01). Expression of CXCR7 protein was higher in muscle invasive bladder cancers than in non-muscle invasive bladder cancers (72. 7% versus 51.9% ,P＜0.05). In patients followed up for 2-95 months, CXCR7 protein expression was significantly higher in patients with recurrence than with non-recurrence (64. 1% versus 32.5%, P＜0.01). Kaplan-Meier analysis and the log-rark test showed that the recurrence-free survival was significantly different between the group of lower CXCR7 expression group and the higher expression group (P＜0.01). Conclusions The expression of CXCR7 protein is high in bladder cancer and the analysis of CXCR7 protein expression is potentially valuable in prognostic evaluation of bladder cancers. CXCR7 may play a role in the development of bladder urothelial cell cancer.     

多沙唑嗪对兔膀胱出口部分梗阻致膀胱顺应性减低的影响

目的 探讨多沙唑嗪对兔膀胱出口部分梗阻后膀胱顺应性改变的影响.方法 成年雄性新西兰兔40只随机分为4组,每组10只,A组为假手术对照组,B组为膀胱出口部分梗阻组,C组为膀胱出口部分梗阻后口服多沙唑嗪组,D组为假手术后给予多沙唑嗪组.各组于14周行尿动力学检测,检测完成后处死并留取膀胱标本,行膀胱称重.结果 4组膀胱标本质量分别为(3.2±0.9)、(14.1±2.3)、(5.0±2.0)、(2.9±0.5)g;B、C组均高于A、D组,B组高于C组,差异均有统计学意义(P＜0.01);A、D组间比较差异无统计学意义(P＞0.05).4组逼尿肌漏尿点压分别为(10.2±2.5)、(18.8±6.1)、(13.5±4.7)、(11.6±3.6)cm H2O(1 cm H2O=0.098 kPa),B组高于A、D组,差异有统计学意义(P＜0.01),且高于C组,差异有统计学意义(P＜0.05);A、C、D组间差异无统计学意义(P＞0.05).膀胱顺应性分别为(2.86±0.56)、(1.22±0.39)、(4.25±2.19)、(2.90±0.53)ml/cm H2O,B组与A、D组相比明显下降,差异有统计学意义(P＜0.01);C组高于A、D组,差异有统计学意义(P＜0.05);A、D组间差异无统计学意义(P＞0.05).结论膀胱出口部分梗阻后早期应用多沙唑嗪治疗能够延迟梗阻对膀胱顺应性的损害,保护膀胱储尿功能.

Abstract：

Objective To explore the effect of doxazosin on rabbit bladder compliance after partial bladder outlet obstruction. Methods A total of 40 male New Zealand white rabbits were randomized into 4 groups, with 10 rabbits in each group. Partial bladder outlet obstruction was established in groups B and C, while groups A and D underwent the same operation but without partial bladder outlet obstruction. On the day after the operation, groups C and D received oral administration of doxazosin. After 14 weeks, urodynamic examinations were carried out in all groups, and the bladder was weighted after cystectomy. Results Bladder weight was (3.2±0.9) g in group A, (14.1±2.3) g in group B, (5.0±2.0) in group C,and (2.9±0.5) g in group D. The bladder weight in groups B and C increased significantly compared to groups A and D (P＜0.01), group B increased significantly over group C (P＜0.01), and there was no significant difference between groups A and D (P＞0.05).The detrusor leak point pressure was (10.2±2.5) cm H2O in group A, (18.8±6.1) cm H2O in group B, (13.5±4.7) cm H2O in group C,and (11.6±3.6) cm H2O in group D. The detrusor leak point pressure in group B was significantly higher than group A, group D (P＜0.01) and group C (P＜0.05). There was no significant difference between group A, group C and group D (P＞0.05). The bladder compliance was (2.86±0.56) ml/cm H2O in group A, (1.22±0.39) ml/cm H2O in group B, (4.25±2.19) ml/cm H2O in group C,and (2.90±0.53) ml/cm H2O in group D. The bladder compliance was significantly decreased in group B compared to groups A and D (P＜0.01). Bladder compliance in group C was significantly higher than in groups A and D (P＜0.05), and there was no significant difference between group A and group D (P＞0.05). Conclusion Early use of doxazosin can delay the occurrence of lower bladder compliance after partial bladder outlet obstruction, thus protecting the storage function of bladder.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

膀胱尿路上皮癌患者外周血T淋巴细胞凋亡蛋白Fas的表达

Objective To investigate the relationship between the Fas expression in peripheral blood T cells and bladder transitional cell carcinoma (TCC). Methods The Fas expression in peripheral blood T cells of 52 patients with TCC and 37 healthy people was detected by flowcytometry. The Fas-posi-tive rate was compared by t test between two designed groups. Results The Fas expression in CD4+ [(20.74±9.02)%] and CD8+[ (7.51±5.93 )% ] was increased in TCC patients as compared with controls ( P < 0. 01 ). Fas-positive CD8+ ceils were reduced in invasive TCC as compared with superficial TCC [ ( 5. 83±3.95 ) % vs ( 5. 83±3.95 ) %, P < 0.05 ], but there was no difference between primary and recurrent cases ( P > 0.05 ). Conclusion The abnormal Fas expression in peripheral blood T cells may play an important role in the development and progression of TCC.     

老年男性下尿路症状伴逼尿肌过度活动患者临床及尿动力学特点分析

Objective To study the change of clinical and urodynamic parameters in the patients with lower urinary tract symptom (LUTS) caused by detrusor overactivity (DO). Methods Two hundred and twenty-seven patients with LUTS underwent clinical evaluation from October 2006 to December 2008, including Prostate Volume (PV), International Prostate Symptom Score (IPSS), Peak Flow rate (PF) and Residual Urine (RU) measurement. Pressure flow studies were performed. The detrusor overactivity was recorded to classify the patients into 2 groups, DO group and none DO group. The clinical and urodynamic parameters were compared between the two groups. Results Mean patient age was 70 years (range 52 to 89). According to the urodynamic results, there were 126 patients in DO group and 101 patients in none DO group. The mean patients age was older in DO group than the none DO group(P＜0.05). Adjusted by age, the PV, PF, and RU were no different between the two groups(P>0.05). The mean first sensation of bladder, bladder compliance, cystometric capacity, bladder outlet obstruction parameters, single voiding volume and max detrusor pressure during contraction were different between the two groups(P＜0.05). Conclusions The main risk factors of DO are the ageing and BOO. The non invasive parameters such as PV、 PF、 and RU could not be used to judge DO. The changes of urodynamic parameters caused by DO were hyperaesthesia of bladder、lower bladder compliance、 higher max detrusor pressure and lower max cystometric capacity. This study emphasis the importance of the urodynamic studies in the aged patients with LUTS.     

RNA干扰下调p53抑制因子iASPP表达对膀胱癌细胞的影响

Objective To discuss the effects of silencing of iASPP gene on human bladder cancer cells. Methods RNAi silencing of iASPP gene in bladder cancer cell 5637 and T24 cells were used by lentiviral mediated interfering short hairpin RNAs. Cell proliferation was tested by MTT assay, and rate of colony was tested by colony formation assay. Cell cycles were tested by using fluorescence-activated cell sorting. Results Down-regulation of iASPP could inhibit the growth and proliferation of human bladder cancer cells (P＜0.05). iASPP know-down could decrease the colony formation of 5637 and T24 cells (P＜0, 05). Knocking down of iASPP in 5637 and T24 cells showed cell arrested at G1. Conclusions Silencing of iASPP gene could inhibit proliferation and colony formation of bladder cancer, iASPP might be an important target for gene therapy of bladder cancer.     

膀胱癌组织中染色体3q26.1小片段高频率缺失及其意义

Objective To investigate the copy number changes on chromosome 3q26. 1 in urothelial carcinoma of the bladder, and to explore its potential clinical significance. Methods The microarray-based comparative genomic hybridization (Array-CGH) approach was used to analyze the genome-wide copy number changes of 35 tumor tissue samples of bladder cancer. To confirm the loss of a small fragment in 3q26. 1 detected by Array-CGH, real-time fluorescent quantitative polymerase chain reaction (real-time PCR) was performed with 57 frozen tumor tissue samples and 34 formalinfixed paraffin-embedded (FFPE) tumor tissue samples. The urine sediment cells collected from 15 healthy volunteers and 29 bladder cancer patients were checked as above. Results The Array-CGH data showed that the copy number loss of a small fragment in 3q26. 1 was detected in 77.1% (27/35)of the tumor tissue samples investigated. Real-time PCR analysis validated this loss of a small fragment of 3q26.1 with high frequencies in both 57 frozen tumor samples and 34 FFPE tumor samples.The percentage of samples exhibiting loss was 78.9% (45/57) and 100. 0% (34/34) respectively.Furthermore, the relative copy number of the 3q26.1 small fragment was significantly lower in the urinary sediment cells of the patients (median=0. 0020), comparing with that of healthy controls (median=0. 0030) (P＜0.01). Conclusions Loss of the small fragment in 3q26.1 could be a characteristic genetic change of urothelial carcinoma of the bladder. It may serve as a potential molecular marker for bladder cancer.